EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?

Abstract excerpt

Background: EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the outcomes of EGFR mutation-positive adenocarcinomas of the lung. In contrast, the significance of EGFR mutation in metastatic squamous cell carcinoma (SCC) of the lung has been debated. Methods: All patients with metastatic SCC who underwent EGFR mutation testing at our center from 2010 to 2015 were included for analysis. EGFR kinase...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Diagnosis and Treatment
• Share to Lung Cancer Treatments and Mutations
• Share to RNA modifications and cancer